Effects of glycemic control on refraction in diabetic patients

Hai-Yan Li¹, Guo-Chun Luo¹, Jiang Guo², Zhen Liang¹

¹Department of Endocrinology, the Second People’s Hospital of Shenzhen, Shenzhen 518035, Guangdong Province, China
²Department of Ophthalmology, the Second People’s Hospital of Shenzhen, Shenzhen 518035, Guangdong Province, China

Correspondence to: Guo-Chun Luo, Department of Endocrinology, the Second People’s Hospital of Shenzhen, Shenzhen 518035, Guangdong Province, China. lghun@163.com

Received: 2010-01-21 Accepted: 2010-03-30

Abstract
- AIM: To evaluate the effects of glycemic control on refraction in diabetic patients.
- METHODS: Twenty newly diagnosed diabetic patients were included in this study. The random blood glucose, HbA1c levels, fasting C-peptide and postprandial 2h C-peptide were measured before treatment. The patients with random blood glucose higher than 12.0 mmol/L and HbA1c level higher than 10.0% were selected. Refraction, intraocular pressure, radius of the anterior corneal curvature, depth of the anterior chamber, lens thickness, vitreous length, and axial length were measured on admission and at the end of week 1, 2, 3 and 4 during glycemic control.
- RESULTS: A transient hyperopic change occurred in all the patients receiving glycemic control. The maximum hyperopic change was 1.60D (range 0.50 ± 3.20D). Recovery of the previous refraction occurred between two and four weeks after insulin treatment. There was a positive correlation between the maximum hyperopic changes and the HbA1c levels on admission (r = 0.84, P < 0.05). There was a positive correlation between the maximum hyperopic changes and the daily rate of blood glucose reduction over the first 7 days of the treatment (r = 0.53, P < 0.05). During transient hyperopia, no significant changes were observed in the intraocular pressure, radius of the anterior corneal curvature, depth of the anterior chamber, lens thickness, vitreous length and axial length.
- CONCLUSION: Transient hyperopic changes occur after glycemic control in diabetic patients with severe hyperglycemia. The degrees of transient hyperopia are highly dependent on HbA1c levels before treatment and the rate of reduction of the blood glucose level.
- KEYWORDS: refraction; diabetes mellitus; lens; blood glucose

DOI: 10.3969/j.issn.1672-5123.2010.04.002


INTRODUCTION
During hypoglycemic treatment, some diabetic patients suffer from blurred vision. It is well known that changes of plasma glucose lead to transient refractive error, but the biological basis of refractive changes in the eyes of diabetic patients has not yet been established and the underlying mechanism is still unknown. The authors conducted a prospective study of 40 eyes of 20 diabetic patients who underwent glycemic control for severe hyperglycemia, in an attempt to make an objective evaluation of refractive changes during treatment.

MATERIALS AND METHODS
Subjects The study was conducted on 40 eyes of 20 newly diagnosed diabetic patients who had a plasma glucose level of 12.0 mmol/L or higher, and a glycosylated haemoglobin (HbA1c) of 10.0% or higher on admission. The subjects consisted of 12 men and eight women, with a mean age of 46 years (range 28-58 years).

Methods Blood pressure, body mass index, triglyceride, total cholesterol, low-density lipoprotein, high-density lipoprotein, fasting C-peptide and postprandial 2h C-peptide were measured on admission (Table 1). All patients received insulin treatment to reduce blood glucose. An ophthalmological examination was conducted on admission and at the end of week 1, 2, 3 and 4 during glycemic control. Refraction, intraocular pressure and radius of the anterior corneal curvature were measured in all subjects. A-mode ultrasonography was performed by the same examiner three times in each eye at each examination to measure the lens thickness, depth of the anterior chamber, vitreous length and axial length. The mean value of the three measurements was used for analysis of each biometric parameter. A change in refraction was defined when the refractive change was 0.5 dioptre or more compared with the value on admission. Blood glucose was measured at least four times at the seven day of hypoglycemic treatment. The mean blood glucose value at the seven day (BG₇) was calculated. The daily rate of reduction of blood glucose concentration over the first 7 days of treatment was calculated by the following equation; ∆BG = (BG₀ - BG₇) / 7.

Statistical Analysis The results were presented as mean, and performed with paired Student’s t test and simple regression analysis. P < 0.05 was considered to be statistically significant.
Table 1 Clinical characteristics of the diabetic patients (mean ± SD)

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Blood glucose (mmol/L)</th>
<th>HbA1c (%)</th>
<th>F-CP (ng/mL)</th>
<th>P-CP (ng/mL)</th>
<th>TG (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>45.5 ± 8.10</td>
<td>19.48 ± 5.04</td>
<td>12.20 ± 1.50</td>
<td>1.25 ± 0.41</td>
<td>2.53 ± 0.89</td>
<td>2.34 ± 1.19</td>
</tr>
</tbody>
</table>

TC (mmol/L) | LDL-C (mmol/L) | HDL-C (mmol/L) | BMI (kg/m²) | SBP (mmHg) | DBP (mmHg) |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4.75 ± 0.72</td>
<td>2.88 ± 0.62</td>
<td>0.90 ± 0.11</td>
<td>24.60 ± 2.90</td>
<td>128.80 ± 18.60</td>
<td>77.30 ± 13.60</td>
</tr>
</tbody>
</table>

F-CP: Fasting C-peptide; P-CP: Postprandial 2h C-peptide; TG: Triglyceride; TC: Total cholesterol; LDL-C: Low-density lipoprotein; HDL-C: High-density lipoprotein; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure (1mmHg = 0.133kPa).

Table 2 Ophthalmic parameters of the diabetic patients (mean ± SD)

<table>
<thead>
<tr>
<th></th>
<th>Before hypoglycemic treatment</th>
<th></th>
<th>The peak time of hyperglycemic change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R</td>
<td>L</td>
<td>R</td>
</tr>
<tr>
<td>Intraocular pressure (mmHg)</td>
<td>15.01 ± 2.77</td>
<td>15.30 ± 2.90</td>
<td>15.08 ± 2.60</td>
</tr>
<tr>
<td>Corneal curvature radius (mm)</td>
<td>7.55 ± 0.27</td>
<td>7.58 ± 0.19</td>
<td>7.51 ± 0.18</td>
</tr>
<tr>
<td>Lens thickness (mm)</td>
<td>4.34 ± 0.15</td>
<td>4.36 ± 0.20</td>
<td>4.35 ± 0.15</td>
</tr>
<tr>
<td>Anterior chamber depth (mm)</td>
<td>3.34 ± 0.08</td>
<td>3.35 ± 0.08</td>
<td>3.36 ± 0.08</td>
</tr>
<tr>
<td>Vitreous length (mm)</td>
<td>16.48 ± 0.13</td>
<td>16.49 ± 0.11</td>
<td>16.50 ± 0.14</td>
</tr>
<tr>
<td>Axial length (mm)</td>
<td>23.84 ± 0.62</td>
<td>23.80 ± 0.66</td>
<td>23.86 ± 0.57</td>
</tr>
</tbody>
</table>

R: Right eye; L: Left eye; P < 0.05.

Figure 1 Relation between maximum hyperopic change and HbA1c levels on admission. There was a significant positive correlation between them (r = 0.84, P < 0.05).

Figure 2 Relation between maximum hyperopic change and the daily rate of glucose reduction over the first 7 days of treatment. There was a positive correlation between them (r = 0.53, P < 0.05).

RESULTS

The mean random blood glucose at admission (BGₐ) was 19.5mmol/L (range 12.0-28.6mmol/L) and the mean HbA1c value was 12.2% (range 10.1%-15.3%). A transient hyperopic change occurred in all diabetic patients receiving hypoglycemic treatment. The maximum hyperopic change occurred at the end of the first week in 10 patients, at the end of the second week in 7 patients and at the end of the third week in 3 patients following treatment. A mean maximum hyperopic change was 1.60 dioptres (range 0.50-3.20 dioptres). Refraction gradually returned to the baseline value at the end of the second week in 3 patients, at the end of the third week in 9 patients and at the end of the fourth week in 7 patients. Refraction did not yet returned at the end of the fourth week in one patient, and the patient was lost to follow then.

There was a significant positive correlation between the maximum hyperopic change and HbA1c level on admission (r = 0.84, P < 0.05, Figure 1). There was also a significant positive correlation between the maximum hyperopic change and ΔBG (r = 0.53, P < 0.05, Figure 2). There was no significant correlation between the maximum hyperopic change and random blood glucose on admission (BGₐ), fasting C-peptide, postprandial 2h C-peptide, age, blood pressure, body mass index, triglyceride, total cholesterol, low-density lipoprotein and high-density lipoprotein (P > 0.05).

The intraocular pressure, radius of the anterior corneal curvature, depth of the anterior chamber, lens thickness, vitreous length and axial length at the peak time of hyperopic change did not differ from the respective value measured before treatment was started (P > 0.05, Table 2).

DISCUSSION

It has been reported that decreasing plasma glucose level causes hyperopic change. However, some investigators have observed both myopic and hyperopic changes in diabetic eyes. The mechanism of alteration in blood glucose concentration leading to refractive change in diabetics is not yet clear. The present study investigated the clinical course of the refractive change of 40 diabetic eyes during glycemic control. This study revealed that during treatment of hyperglycemia in diabetic patients, a transient hyperopic change of 0.5 dioptre or more developed in all eyes. Hyperopic
change gradually returned to the baseline value within four weeks in most patients. After receiving hypoglycemic treatment, some diabetic patients complain of blurred vision because of refractive change and new glasses are prescribed. However, new glasses will not fit after 2 or 4 weeks. So doctors should explain the refractive change is transient and the prescription of new glasses should be delayed. If glasses must be prescribed during the occurrence of transient hyperopia, further modifications in the prescription may be needed when the refraction returns stable.

In the present study, patients who had a higher HbA1c on admission had a larger maximum hyperopic change. There was a definite positive correlation between the maximum hyperopic change and the daily rate of plasma glucose reduction over the first 7 days during glycemic control. However, there was no significant correlation among the maximum hyperopic change and each of age, body mass index, blood pressure, lipid, and C-peptide level. These results indicate that the degree of hyperopia is highly dependent on the rate of plasma glucose reduction and the degree of hyperglycemia. No significant correlation was observed between the maximum hyperopic change and random blood glucose on admission \( (P = 0.06) \). It is probably because that HbA1c is more accurate than random blood glucose in reflecting hyperglycemia degree.

Lens abnormalities have been suggested as a cause of refraction error in diabetic patients. Excess glucose in the lens is converted to sorbitol during hyperglycemia. Sorbitol is poorly permeable and accumulates in the lens. When blood glucose reduces, the difference in osmotic pressure results in the influx of water from the aqueous humour into the lens, causing lenticular swelling\(^3,6,7\). However, an increase in lens thickness would promote myopic changes through increase of refractive power, which seems to be contradictory with the observation of hyperopic changes when plasma glucose reduces. The hypothesis is that lens cortex hydration following the influx of water from the aqueous humour results in the decrease of refractive power, which might be involved in the development of transient hyperopic change. The morphological change of the lens is minor. The present study found no significant changes in the lens thickness, depth of the anterior chamber and axial length, which supports the above hypothesis.

Overall, a transient hyperopic change occurred in diabetic patients during glycemic control. The degree of hyperopia is highly dependent on the HbA1c level before treatment and the rate of plasma glucose reduction over the first 7 days of treatment. It might be the mechanism that lens cortex hydration results in the decrease of refractive power, not that the morphology of lens changes.

**REFERENCES**


**降糖治疗对糖尿病患者眼屈光度的影响**

李海燕\(^1\), 罗国贤\(^2\), 郭 磊\(^2\), 梁 真\(^2\)

（作者单位：518035 中国广东省深圳市第二人民医院\(^1\)内分泌科;\(^2\)眼科）

作者简介：李海燕，女，主治医师，研究方向：糖尿病及其并发症的防治。

通讯作者：罗国贤，男，主任医师，中华医学会糖尿病学分会委员，中国医师协会内分泌代谢医师分会委员，广东省医学会内分泌学分会常务委员，深圳市医学会糖尿病学分会主任委员，研究方向：内分泌代谢疾病的诊治。lshun@163.com

**摘要**

目的：分析降糖治疗对糖尿病患者眼屈光度的影响。

方法：新诊断的糖尿病患者20例，检测治疗前期血糖，糖化血红蛋白（HbA1c），空腹及餐后2h C 肽。测定双眼屈光度，角膜曲率，前房深度及晶状体厚度，并在降糖治疗1，2，3,4wk分别复测以上眼部指标。分析屈光度改变与各生化指标的相关性及降糖治疗前后各眼部指标的变化。

结果：降糖治疗后所有患者均出现远近视性屈光改变，改变幅度与HbA1c和治疗1wk的降糖速度呈正相关，与治疗前期血糖、空腹及餐后2h C 肽无相关性，持续约2～4wk逐渐恢复至治疗前屈光水平。治疗前后，角膜曲率、前房深度和晶状体厚度等未见显著性变化。

结论：降糖治疗导致糖尿病患者出现暂时性远视改变，改变幅度主要取决于治疗前HbA1c水平及前7d的降糖速度。其发生机制可能与晶状体水合化导致的屈光力降低有关，而非晶状体形态的改变。

**关键词**：屈光度; 糖尿病; 晶状体; 血糖